Xanthine oxidase and uric acid in atrial fibrillation

Frontiers in Physiology

Volumn 3 MAY, Issue , 2012, Pages

  Korantzopoulos, Panagiotis ^a   Letsas, Konstantinos P ^b   Liu, Tong ^c  

^a UNIVERSITY OF IOANNINA   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

^c SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866429018     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2012.00150     Document Type: Article

References (40)

1. Cai, H., Li, Z., Goette, A., Mera, F., Honeycutt, C., Feterik, K., Wilcox, J. N., Dudley, S. C. Jr., Harrison, D. G., and Langberg, J. J. (2002).Downregulationof endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke. Circulation 106, 2854-2858.
2. Chrysohoou, C., Pitsavos, C., Barbetseas, J., Brili, S., Kotroyiannis, I., Papademetriou, L., Metallinos, G., Skoumas, J., Tentolouris, C., and Stefanadis, C. (2008). Serum uric acid levels correlate with left atrial function and systolic right ventricular function in patients with newly diagnosed heart failure: the hellenic heart failure study. Congest. Heart Fail. 14,229-233.
3. Das, R. R., Seshadri, S., Beiser, A. S., Kelly-Hayes, M., Au, R., Himali, J. J., Kase, C. S., Benjamin, E. J., Polak, J. F., O'Donnell, C. J., Yoshita, M., D'Agostino, R. B. Sr., DeCarli, C., and Wolf, P.A. (2008).Prevalence andcor-relates of silent cerebral infarcts in the Framingham offspring study. Stroke 39,2929-2935.
4. Dawson, J., and Walters, M. (2006). Uric acid and xan-thine oxidase: future therapeutic targets in the prevention of cardiovascular disease? Br. J. Clin. Pharmacol. 62, 633-644.
5. Doehner, W., and Landmesser, U. (2011). Xanthine oxidase and uric acid in cardiovascular disease: clinical and therapeutic options. Semin. Nephrol. 31,433-440.
6. Dudley, S. C. Jr., Hoch, N. E., McCann, L. A., Honeycutt, C., Diamandopoulos, L., Fukai, T., Harrison, D. G., Dikalov, S. I., and Langberg, J. (2005). Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the NADPH and xanthine oxidases. Circulation 112, 1266-1273.
7. Feig, D. I., Soletsky, B., and Johnson, R. J. (2008). Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 300, 924-932.
8. George, J., and Struthers, A. D. (2008). The role of urate and xanthine oxidase inhibitors in cardiovascular disease. Cardiovasc. Ther. 26, 59-64.
9. Glantzounis, G. K., Tsimoyiannis, E. C., Kappas, A. M., and Galaris, D. A. (2005). Uric acid and oxidative stress. Curr. Pharm. Des. 11,4145-4151.
10. Grum, C. M., Gallagher, K. P., Kirsh, M. M., and Shlafer, M. (1989). Absence of detectable xanthine oxidase in human myocardium. J. Mol. Cell. Cardiol. 21, 263-267.
11. Hellsten-Westing, Y. (1993). Immunohistochemical localization of xanthine oxidase in human cardiac and skeletal muscle. Histochemistry 100,215-222.
12. Heo, S. H., and Lee, S. H. (2010). High levels of serum uric acid are associated with silent brain infarction. J. Neurol. Sci. 297, 6-10.
13. Hoeper, M. M., Hohlfeld, J. M., and Fabel, H. (1999). Hyperuricaemia in patients with right or left heart failure. Eur. Respir. J. 13, 682-685.
14. Kelkar, A., Kuo, A., and Frishman, W. H. (2011). Allopurinol as a cardiovascular drug. Cardiol. Rev. 19,265-271.
15. Kim, S. Y., Guevara, J. P., Kim, K. M., Choi, H. K., Heitjan, D. F., and Albert, D. A. (2009). Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum. 61, 885-892.
16. Kim, Y. M., Guzik, T. J., Zhang, Y. H., Zhang, M. H., Kattach, H., Ratnatunga, C., Pillai, R., Channon, K. M.,and Casadei, B. (2005). A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ. Res. 97, 629-636.
17. Korantzopoulos, P., Kolettis, T. M., Galaris, D., and Goudevenos, J. A. (2007). The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int.J. Cardiol. 115, 135-143.
18. Kuwabara, M., Niwa, K., and Niinuma, H. (2012). Hyperuricemia is an independent risk factor of atrial fibrillation due to electrical remodeling through activation of uric acid transporter [Abstr act]. ACC 2012. J.Am. Coll. Cardiol. 59(Suppl.A), A163.
19. Landmesser, U., Spiekermann, S., Preuss, C., Sorrentino, S., Fischer, D., Manes, C., Mueller, M., and Drexler, H. (2007). Angiotensin II induces endothelial xanthine oxidase activation: role for endothelial dysfunction in patients with coronary disease. Arterioscler. Thromb. Vasc. Biol. 27, 943-948.
20. Letsas, K. P., Korantzopoulos, P., Filippatos, G. S., Mihas, C. C., Markou, V., Gavrielatos, G., Efremidis, M., Sideris, A., and Kardaras,F. (2010). Uric acid elevation in atrial fibrillation. Hellenic J. Cardiol. 51, 209-213.
21. Letsas, K. P., Siklódy, C. H., Korantzopoulos, P., Weber, R., Bürkle, G., Mihas, C. C., Kalusche, D., and Arentz, T. (2011). The impact of body mass index on the efficacy and safety of catheter ablation of atrial fibrillation. Int. J. Cardiol. PMID: 21726910. [Epub ahead of print].
22. Liu, T., Zhang, X., Korantzopoulos, P., Wang, S., and Li, G. (2011). Uric acid levels and atrial fibrillation in hypertensive patients. Intern. Med. 50, 799-803.
23. Liu, Y., Liu, H., Dong, L., Chen, J., and Guo, J. (2010). Prevalence of atrial fibrillation in hospitalized patients over 40 years old: ten-year data from the People's Hospital of Peking University. Acta Cardiol. 65, 221-224.
24. MacGowan, S. W., Regan, M. C., Malone, C., Sharkey, O., Young, L., Gorey, T. F., and Wood, A. E. (1995). Superoxide radical and xanthine oxidoreductase activity in the human heart during cardiac operations. Ann. Thorac. Surg. 60, 1289-1293.
25. Moutzouri, E., Liberopoulos, E. N., Florentin, M., Liamis, G., and Elisaf, M. S. (2012). Effects of statin mono-therapy versus statin plus ezetimibe combination on serum uric acid levels. J. Cardiovasc. Pharmacol. Ther. PMID: 22539817. [Epub ahead of print].
26. Ndrepepa, G., Braun, S., Haase, H. U., Schulz, S., Ranftl, S., Hadamitzky, M., Mehilli, J., Schömig, A., and Kastrati, A. (2012). Prognostic value of uric acid in patients with acute coronary syndromes. Am. J. Cardiol. 109, 1260-1265.
27. Negi, S., Sovari, A. A., and Dudley, S. C. Jr. (2010). Atrial fibrillation: the emerging role of inflammation and oxidative stress. Cardiovasc. Hematol. Disord. Drug Targets 10, 262-268.
28. Noman, A., Ang, D. S., Ogston, S., Lang, C. C., and Struthers, A. D. (2010). Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 375, 2161-2167.
29. Ruggiero, C., Cherubini, A., Ble, A., Bos, A. J., Maggio, M., Dixit, V. D., Lauretani, F., Bandinelli, S., Senin, U.,and Ferrucci, L. (2006). Uric acid and inflammatory markers. Eur. HeartJ. 27, 1174-1181.
30. Sakabe, M., Fujiki, A., Sakamoto, T., Nakatani, Y., Mizumaki, K., and Inoue, H. (2012). Xanthine oxidase inhibition prevents atrial fibrillation in a canine model of atrial pacing-induced left ventricular dysfunction.J. Cardiovasc. Electrophysiol. (in press). doi: 10.1111/j.1540-8167.2012.02356.x
31. Schotten, U., Verheule, S., Kirchhof, P., and Goette, A. (2011). Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol. Rev. 91, 265-325.
32. Shi, Y., Evans, J. E., and Rock, K. L. (2003). Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425, 516-521.
33. Suzuki, S., Sagara, K., Otsuka, T., Matsuno, S., Funada, R., Uejima, T., Oikawa, Y., Koike, A., Nagashima, K., Kirigaya, H., Yajima, J., Sawada, H., Aizawa, T., and Yamashita, T. (2012). Gender-specific relationship between serum uric Acid level and atrial fibrillation prevalence. Circ. J. 76, 607-611.
34. Tamariz, L., Agarwal, S., Soliman, E. Z., Chamberlain, A. M., Prineas, R., Folsom, A. R., Ambrose, M., and Alonso, A. (2011). Association of serum uric acid with incident atrial fibrillation (from the Atherosclerosis Risk In Communities [ARIC] study). Am. J. Cardiol. 2011, 108, 1272-1276.
35. Van Wagoner, D. R. (2003). Molecular basis of atrial fibrillation: a dream or a reality? J. Cardiovasc. Electrophysiol. 14, 667-669.
36. Van Wagoner, D. R. (2008). Oxidative stress and inflammation in atrial fibrillation: role in pathogenesis and potential as a therapeutic target. J. Cardiovasc. Pharmacol. 52, 306-313.
37. Wakili, R., Voigt, N., Kaab, S., Dobrev, D., and Nattel, S. (2011). Recent advances in the molecular patho-physiology of atrial fibrillation. J. Clin. Invest. 121, 2955-2968.
38. Watanabe, E. (2012). Uric acid and atrial fibrillation -cause or other association? Circ. J. 76, 584-585.
39. Wei, L., Mackenzie, I. S., Chen, Y., Struthers, A. D., and MacDonald, T. M. (2011). Impact of allopurinol use on urate concentration and cardiovascular outcome. Br. I Clin. Pharmacol. 71, 600-607.
40. Weimert, N. A., Tanke, W. F., and Sims, J. J. (2003). Allopurinol as a cardioprotectant during coronary artery bypass graft surgery. Ann. Pharmacother. 37, 1708-1711.